Until law, GLP-1 drugs were used to treat diabetes, obesity and even the recent evidences suggest that it could as well be used to treat chronic kidney problems. There is yet another research, published in JAMA Psychiatry on February 25, titled Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial that explores if GLP-1 receptor agonist semaglutide reduce alcohol consumption and cravings in adults with alcohol use disorder.

What Do Studies Say?

The research was conducted over a period of 9 weeks, where in the randomized clinical trial, the participants who were administered semaglutide, it led to reductions in some but not all measures of weekly consumptions. It also reduced weekly alcohol and craving related to placebo, and also led to a greater relative reduction in cigarettes per day.

The research also found that weekly injections of semaglutide, which is the active ingredient in weight loss drugs like Wegovy also helped reduce cravings in people with alcohol use disorder.

The lead author Christian Hendershot said that these findings will help in developing new approaches to treat alcoholism. "Two drugs currently approved to reduce alcohol consumption aren't widely used. The popularity of Ozempic and other GLP-1 receptor agonists increases the chances of broad adoption of these treatments for alcohol use disorder," said Hendershot in news release by the University of Southern California's Institute for Addiction Research, where he is the director.

The study is government-funded research and was funded by the National Institute on Alcohol Abuse and Alcoholism, part of the National Institutes of Health.

How Was The Study Conducted?

The study was small, and took in account for only 48 adults over two months, thus experts say that it is not yet clear how safe these drugs are for people who do not need to lose weight. Though the results do add up with the evidence form animal studies on drugs like Ozempic and Wegovy on how it helps manage cravings, not just for food, but also for tobacco and alcohol. Scientists are also studying these drugs on smokers, people with opioid addiction and cocaine users.

Co-author Dr Klara Klein of the University of North Carolina at Chapel Hill who treats people with obesity and diabetes said, "This is such promising data. And we need more of it. We frequently will hear that once people start these medications that their desire to drink is very reduced, if not completely abolished."

Why Does It Work So Well Against Alcoholism?

The GLP-1 receptor agonists work by mimicking hormones GLP-1 in the gut and brain that regulates appetite and feelings of fullness. This response is what helps one lose weight, and what helps one curb their craving for alcohol. These drugs that mimic the functioning of your brain, which is responsible to tell your body when to stop consuming, are the same hormones that tell your body about other kinds of consumptions, including alcohol. Therefore by consuming the weight loss drugs one can treat alcohol use disorder.

However, the researchers have pointed out on the limited data on the research and have suggested to continue using the three approved drugs by the National Institute on Alcohol Abuse and Alcoholism and Substance Abuse and Mental Health Services Administration, namely, Disulfiram, Naltrexone, and Acamprosate to treat alcohol use disorder until large studies confirm these findings.

US Department of Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. has announced food policy reforms as part of efforts to implement President Donald Trump’s Make America Healthy Again (MAHA) initiative.

The proposed measures focus on two areas: greater oversight of food ingredients and establishing a standardized federal definition of ultra-processed foods.

As per Kennedy, “nearly 60% of the American diet is made up of ultra-processed foods, and childhood obesity now affects more than one in five American children”.

To counter this, transforming the food system is key, he said.

“These historic actions bring greater transparency to what’s in our food and stronger science to federal nutrition policy. President Trump and I promised to Make America Healthy Again, and today we are turning that promise into policy,” Kennedy said.

What Are the Proposed Changes?

HHS has proposed a rule that would require manufacturers to notify the US Food and Drug Administration (FDA) when they determine that a substance added to human or animal food is Generally Recognized as Safe (GRAS).

In addition, HHS and the US Department of Agriculture (USDA) have submitted for final review the federal government’s first proposed definition of ultra-processed foods (UPFs).

Acting FDA Commissioner Kyle Diamantas said the measures are intended to increase transparency and strengthen science-based oversight of ingredients entering the food supply.

“By proposing mandatory GRAS notifications, we are closing critical information gaps and giving the FDA greater visibility into substances entering the food supply,” Diamantas said.

He added that the proposed UPF definition could provide a stronger foundation for future nutrition research.

What Is GRAS?

GRAS stands for Generally Recognized as Safe. It refers to substances that are considered safe by qualified experts for their intended use and are therefore exempt from the standard premarket approval requirements for food additives.

Examples of GRAS ingredients include canola oil, vinegar and spices such as black pepper.

Under the proposed rule, manufacturers would be required to notify the FDA when they conclude that a substance qualifies as GRAS. The agency would also expand its public-facing inventory of submitted GRAS notices.

According to Diamantas, mandatory notifications would help close information gaps and give the FDA greater visibility into substances entering the food supply.

First Federal Definition of Ultra-Processed Foods

HHS and USDA have submitted for final review the federal government’s first proposed definition of ultra-processed foods.

Research has linked high consumption of UPFs with preventable chronic diseases, including type 2 diabetes and heart disease. However, the absence of a standardized federal definition has made it difficult to maintain consistency in research across federal agencies.

The proposed definition incorporates feedback from thousands of stakeholders, including industry representatives, consumer organizations, researchers and members of the public.

Diamantas said the definition could help “create a stronger foundation for future nutrition research.”

How Does This Support Trump’s MAHA Agenda?

The measures are part of the Trump administration’s Make America Healthy Again Strategy and build on efforts to strengthen nutrition science, improve transparency and modernize oversight of the US food supply.

HHS also encouraged Congress to build on these efforts through legislation aimed at further strengthening the safety of the American food supply.

The death toll from Ebola has crossed 2,000 in the Democratic Republic of the Congo (DRC), three months after the outbreak was officially declared in May.

The outbreak has caused 4,381 confirmed cases across five provinces, making it the fastest-growing Ebola outbreak recorded in the Central African country. The response has been complicated by strikes by unpaid health workers, misinformation and cultural practices.

Ebola Virus Outbreak Began in February

The outbreak is caused by the rare Bundibugyo strain of Ebola, for which there is currently no approved treatment or vaccine.

According to the World Health Organization (WHO), the virus first emerged in the DRC in February, about three months before the outbreak was officially declared in the DRC and neighboring Uganda on May 15.

Some early patients were reportedly treated for malaria or typhoid, which can initially cause fever, weakness, vomiting and diarrhea. Early testing also focused on the more common Zaire strain of Ebola, delaying recognition of the Bundibugyo virus.

By early May, WHO had identified an unusual cluster of severe illness and deaths in the Mongbwalu health zone in Ituri Province. An investigation covering April 15 to May 13 subsequently identified 246 suspected cases and 65 deaths across three health zones.

The response has also been affected by conditions in Ituri, including armed conflict, population displacement and poor road access. Health workers have faced shortages of protective equipment, while some healthcare facilities have been affected by workers' strikes.

Zoonotic Spillover Likely Triggered the Outbreak

A new study published in Nature Medicine suggests that the outbreak began through a zoonotic spillover event, meaning the virus jumped from animals to humans before spreading between people.

Researchers from Congo, Uganda, Belgium and other countries found that the outbreak strain was genetically distinct from Bundibugyo Ebola viruses identified during previous outbreaks in 2007 and 2012.

The findings are consistent with a new animal-to-human transmission event, followed by sustained human-to-human transmission.

The study did not identify the specific animal source. However, Ebola viruses are known to periodically spill over from infected animals into human populations.

Genetic analysis also confirmed that cases detected in Uganda were linked to the outbreak in Congo.

How Was the Study Conducted?

Bundibugyo virus disease (BVD) outbreaks were previously recorded in 2007–2008 in Bundibugyo District, Uganda, and in 2012 in Isiro, DRC.

For the 2026 outbreak, researchers generated 22 viral genomes from samples collected from patients with BVD in the DRC and Uganda.

The genomes formed a well-supported phylogenetic cluster separate from variants associated with the 2007 and 2012 outbreaks. The analysis also showed evidence of sustained human-to-human transmission.

The researchers called for greater decentralized laboratory diagnostic capacity, including pan-Orthoebolavirus testing and genomic sequencing, to improve early detection and control of future outbreaks.

How Does Ebola Spread From Animals to Humans?

Ebola can jump to humans from infected animals such as bats, monkeys and apes. Transmission can occur through contact with blood, body fluids, excrement or raw meat during hunting and butchering.

Once the virus enters the human population, it can spread from person to person through contact with infected bodily fluids.

Symptoms of Bundibugyo Virus Disease

Symptoms of Bundibugyo virus disease are similar to those caused by other Ebola viruses and can include:

• Fever
• Headache
• Muscle pain
• Weakness
• Diarrhea
• Vomiting
• Stomach pain
• Unexplained bleeding or bruising, usually in later stages of illness

What if one blood sample could detect symptoms of multiple cancers at once, while also disclosing which organ may be affected? A new study from UCLA has brought that possibility a step closer to reality.

Researchers have at UCLA have developed a blood test called MethylScan that can detect molecular signals linked to multiple cancers and other diseases by analysing DNA fragments circulating in the bloodstream.

The findings, published in the Proceedings of the National Academy of Sciences, suggest the test could offer a simpler and potentially cheaper way to screen for serious diseases like cancer before their symptoms appear.

How Can One Blood Test Detect Different Cancers?

A blood test may be able to detect multiple cancers at once due to cell-free DNA (cfDNA). Every day, billions of cells die and release tiny fragments of DNA into the bloodstream. These fragments carry information about where they came from and what is happening in that tissue.

Instead of primarily searching for cancer-causing mutations, MethylScan looks at DNA methylation, a type of chemical tags that regulate how genes behave.

Different organs have distinct methylation patterns, and those patterns can change when cells become cancerous or diseased.

“DNA methylation reflects the health status of a tissue. It’s a very informative signal,” said Dr Wenyuan Li, professor of pathology and laboratory medicine at UCLA.

The researchers also developed a method to filter out the DNA released by normal blood cells, reducing the "background noise” that can make early cancer signals difficult to detect.

Also read: Studying Live Cancer Cells Could Transform Drug Discovery; Researchers Turn Cell Biology Into ‘Live Cinema’

What Are The Study's Findings?

The researchers tested MethylScan using blood samples from 1,061 people, including patients with liver, lung, ovarian and stomach cancers, people with liver diseases and healthy participants.

At 98% specificity, the test detected about 63% of cancers across all stages. For early-stage cancers, its sensitivity was around 55%.

The test also showed promise in identifying where an abnormal signal originated. This could help as a positive blood test would still need to be followed by imaging or other diagnostic tests.

“Being able to trace signals back to their source is important because a positive blood test needs to be followed by imaging or other diagnostic procedures directed at the right organ,” Li said.

Also read: Tudriqev: US FDA Approves Replimune's Skin Cancer Drug After Rejecting It Twice

Early Cancer Detection Is Key

“Early detection is crucial,” said Dr Jasmine Zhou, the study’s senior author. “Survival rates are far higher when cancers are caught before they spread.”

The findings are promising, but larger trials will be needed to establish whether such tests can reliably detect cancers in people who have no symptoms.

Also read: Following A Western Diet? Changes In Your Gut Bacteria Could Increase Colon Cancer Risk

More Developments In The Field

The findings come as another multi-cancer test, Galleri, is designed to detect signals from more than 50 cancers from a single blood sample.

Reuters reported this month that the US FDA plans to convene an advisory panel in September to review its application for approval.

But experts continue to stress that these tests are not replacements for established screening, such as mammograms or colonoscopies.